Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia
Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia
This is an open-label study to determine the pharmacokinetics, safety and tolerability of single ascending doses of lumateperone long-acting injectable formulation in patients with schizophrenia.
- Trial name
- NCT04709224
- Testing
- Lumateperone Long-Acting Injectable
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Bipolar Disorder, Schizophrenia
A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)
The basic hypothesis of this trial is that forgetfulness and failure to establish a routine that facilitates medication adherence are prominent reasons for non-adherence.
- Trial name
- SEQUEL (NCT00533260)
- Where
- 35 sites in Netherlands
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Schizophrenia
Non-interventional Study -Observe Treatment Efficacy in Maintaining Symptoms Control in Schizophrenia With Seroquel XR
the primary purpose of the study is to observe symptoms control in schizophrenia for 6 months in patients treated with Seroquel XR. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation.
- Trial name
- NCT00750087
- Where
- 32 sites in Romania
- Volunteers
- 578 people
- Sponsor
- AstraZeneca
Tardive Dyskinesia
Pyridoxal Kinase Activity in Tardive Dyskinesia
Objectives: The mechanisms of tardive dyskinesia (TD) remain unclear, although pathophysiologic theories have proposed mechanisms such as dopamine receptor supersensitivity, the degeneration of cholinergic striatal interneurons…
- Trial name
- NCT01908452
- Testing
- Pyridoxine
- Where
- 3 sites in Israel
- Sponsor
- Beersheva Mental Health Center
Schizophrenia, Episodic Memory Deficits
Testing Effect and Schizophrenia
When people are tested on a previously learned material, they will latter remember it better even when compared to a condition where they can re-study it.
- Trial name
- NCT02150174
- Testing
- Retrieval practice effect using word pairs and cued recall tests with feedback
- Where
- 2 sites in France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Substance Use Disorder, Attention Deficit Disorder With Hyperactivity
tRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients
The purpose of this study is to study the efficacy and security of noninvasive brain stimulation as a new approach for patients with Substance Use Disorders (SUDs) plus other psychiatric conditions like ADHD, Schizophrenia…
- Conditions
- Substance Use Disorder, Attention Deficit Disorder With Hyperactivity, Bipolar Disorder, Schizophrenia
- Trial name
- tRND&SUDs (NCT01876524)
- Testing
- Transcranial Random Noise Stimulation
- Where
- Spain
- Volunteers
- 225 people
- Sponsor
- Spanish Foundation for Neurometrics Development
Bipolar Disorder, Schizophrenia
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
- Conditions
- Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder
- Trial name
- NCT06041646
- Testing
- Sublingual film containing Igalmi
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioXcel Therapeutics Inc
Affective Psychosis, Bipolar, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while…
- Conditions
- Affective Psychosis, Bipolar, Bipolar Disorder, Mania
- Trial name
- NCT00309686
- Testing
- Paliperidone ER
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia
Primary Objective: To evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia.
- Trial name
- NCT06253546
- Testing
- TV-44749 318mg, Oral Olanzapine 10mg/day, TV-44749 425mg
- Where
- 6 sites in China
- Volunteers
- 24 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Affective Psychosis, Bipolar, Mania
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
- Conditions
- Affective Psychosis, Bipolar, Mania, Manic-Depressive Psychosis
- Trial name
- NCT00454883
- Testing
- ziprasidone
- Volunteers
- 379 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Apathy, Schizophrenia
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician …
- Conditions
- Apathy, Schizophrenia, Schizophrenia; Psychosis
- Trial name
- NCT06482554
- Testing
- Lumateperone 42 mg, Risperidone 2 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Schizophrenia
Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in Patients With Schizophrenia: a Real-life Study
This study aims to examine the dual effects of cannabis consumption on both positive and negative symptoms of schizophrenia, across laboratory and real-world contexts.
- Trial name
- F_r_IEND-3 (NCT07309159)
- Testing
- Ecological Momentary Assessment (EMA) and Reality Monitoring tasks
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Charles Perrens, Bordeaux
Schizophrenia
Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids
This research study helps to demonstrate that adding vitamins and fats (nutritional supplements) to a diet will help reduce body weight and improve the lipid profile.
- Trial name
- NCT00211562
- Testing
- Olanzapine, Omega 3, Vitamin E+C
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Augusta University
Schizophrenia, Schizoaffective Disorder
Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder
This twelve month, open-label study considers the effect of Risperdal (risperidone) versus Zyprexa (olanzapine) on weight gain, physical health, and outcome in a population of those diagnosed with schizophrenia, schizoaffective…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
- Trial name
- NCT00179062
- Testing
- olanzapine versus risperidone
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Vanderbilt University
Schizophrenia
A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia
This study is designed to assess the safety and tolerability of the effects of XEP527, with particular emphasis on disease status and its compatibility with the standard of care in patients with stable schizophrenia.
- Trial name
- NCT07908680
- Testing
- XEP527
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
The purpose of this study is to evaluate the pharmacokinetics (study of what the body does to a drug) and safety of paliperidone palmitate ranging from 75 to 150 milligram equivalents in repeated doses (4 injections) administered…
- Trial name
- NCT01942382
- Testing
- Paliperidone palmitate
- Volunteers
- 76 people
- Sponsor
- Janssen Pharmaceutical K.K.
Equine-Assisted Therapy, Schizophrenia
Hippotherapy in Patients With Schizophrenia
This study will determine the efficacy of hippotherapy (horseback-riding) program, as an adjuvant to standard psychiatric treatment, on the outcomes of patients with schizophrenia.
- Trial name
- NCT06303596
- Testing
- Hippotherapy, Standard psychiatric treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people
- Sponsor
- Erzurum Technical University
Depression - Major Depressive Disorder, Schizophrenia Disorders
Development and Application of Precision Treatment Strategies for Common Mental Disorders
Schizophrenia (SCH), major depressive disorder (MDD), and bipolar disorder (BPD) are prevalent, disabling psychiatric conditions that not only cause significant suffering for affected individuals and their families but also…
- Conditions
- Depression - Major Depressive Disorder, Schizophrenia Disorders, Bipolar Disorder (BD)
- Trial name
- NCT06729541
- Testing
- Multigenetic Pharmacogenomics-Guided Treatment (MPGT)
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
Schizophrenia Disorders, Cognitive Impairment
Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and
ACT combined with stratified intervention improved cognitive function and quality of life in elderly schizophrenia patients by enhancing psychological flexibility and family support.
- Conditions
- Schizophrenia Disorders, Cognitive Impairment, Acceptance and Commitment Therapy
- Trial name
- NCT06949657
- Testing
- the conventional treatment group, the ACT group
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Third People's Hospital, Huzhou City, Zhejiang Province, China
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder
- Trial name
- NCT00061802
- Testing
- risperidone, quetiapine
- Where
- 13 sites in United States, India and 1 more
- Volunteers
- 225 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.